Immunotherapy is a promising new treatment for patients suffering from glioma, in particular glioblastoma multiforme (GBM). However, tumour cells use different mechanisms to escape the immune responses induced by the treatment. As many other tumours, gliomas express or secrete several immunosuppressive molecules that regulate immune cell functions. In this study, we first analysed FasL, HLA-G, IDO, PDL-1 and TGF-β1, -β2 and -β3 expression by transcriptomic microarray analysis in a series of 20 GBM samples and found respectively 15%, 60%, 85%, 30%, 70%, 80% and 35% of positive specimens. mRNA expression was then confirmed in 10 GBM primary cell lines and 2 immortalised cell lines U251 and U87MG. Furthermore, the protein expression of PDL-1, IDO activity and TGF-β2 secretion were found on most of the untreated GBM primary cell lines. Remarkably, treatment with IFN-γ increased the PDL-1 cell surface expression and the IDO activity, but reduced the TGF-β2 secretion of GBM cell lines. We finally analysed the immunosuppressive effects of IDO, PDL-1 and TGF-β1-3 by measuring IFN-γ production and cell cytotoxicity activity of tumour antigen-specific T cells. PDL-1 partially affected the IFN-γ production of antigen-specific T cells in response to GBM primary cell lines, and IDO inhibited lymphocyte proliferation induced by lectins. None of these molecules directly affected the T cell cytotoxicity function. Due to the functional role of PDL-1 and IDO molecules expressed by GBM cells, one could expect that blocking these molecules in the immunotherapy strategies would reinforce the efficiency of these treatments of GBM patients.
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Introduction
Glioblastoma multiforme, the most common primary brain tumour in adults, is an attractive target for novel therapies regarding its poor prognosis with standard treatment including total surgical resection, radiotherapy and adjuvant chemotherapy (Stupp et al., 2005) . Indeed, despite intensive investigations for novel drugs, less than a third of patients survive more than two years (Stupp et al., 2009) . Recurrence of GBM occurs most often within few months due to the re-growth of remaining tumour cells that are resistant to both radiotherapeutic and chemotherapeutic agents.
Cellular immunotherapy in gliomas, one of the promising new therapies, has shown convincing results in terms of induction of antitumour immune responses and prolonged survival compared with control groups receiving conventional chemotherapy and radiotherapy (Yamanaka, 2008) . In particular, patients treated with dendritic cell vaccinations have demonstrated systemic antigen-specific cytotoxicity and intra-tumour infiltration of cytotoxic T cells (Yamanaka et al., 2003; Kikuchi et al., 2004; Yu et al., 2004; Yamanaka et al., 2005) . Liau et al. recently reported that T cell infiltration within the tumour was inversely correlated with the secretion of Transforming Growth Factor-beta 2 (TGF-β2) by the glioma cells (Liau et al., 2005) , highlighting the impact of the immunosuppressive properties of the tumour on the clinical efficiency of the treatment.
Local and systemic immune suppression has been involved in glioma progression (Weller and Fontana, 1995; Walker et al., 2002) . TGF-β2, originally defined as the glioblastoma cell-derived T cell suppressor factor, is a molecule that suppresses T cell growth and inhibits T cell activation and differentiation into effector cells (Gorelik and Flavell, 2002) . Several other intracellular, membrane and soluble molecules such as FasL, HLA-G, PDL-1 (for Programmed cell Death Ligand-1, CD274), IDO (for Indoleamine2,3-DiOxygenase) and TGF-β1-3 have been described as taking part in this phenomenon. The Fas ligand (FasL, 
